71639-13-9

Basic information

• Product Name: diethyl 2-(3-nitrophenylethyl)malonate
• Synonyms: diethyl 2-(3-nitrophenylethyl)malonate
• CAS NO: 71639-13-9
• Molecular Weight: 309.319
• Mol File: 71639-13-9.mol
• Article Data: 37

Chemical Properties

• CAS DataBase Reference: diethyl 2-(3-nitrophenylethyl)malonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 2-(3-nitrophenylethyl)malonate(71639-13-9)
• EPA Substance Registry System: diethyl 2-(3-nitrophenylethyl)malonate(71639-13-9)

Safety Data

• Hazardous Substances Data: 71639-13-9(Hazardous Substances Data)

Upstream product

• 5153-67-3 nitrostyrene 
• 996-82-7 sodium diethylmalonate 
• 102-96-5 (2-nitroethenyl)benzene 
• 105-53-3 diethyl malonate 
• 75-52-5 nitromethane 
• 5292-53-5 diethyl benzalmalonate 
• 104-88-1 4-chlorobenzaldehyde 
• 101671-01-6 1-nitro-2-(4-chlorophenyl)ethylene 
• 37892-24-3 potassium diethyl malonate 
• 100-52-7 benzaldehyde 
• 1164124-57-5 (2R,3S)-diethyl 2-nitro-3-phenylcyclopropane-1,1-dicarboxylate 
• 685-87-0 Diethyl 2-bromomalonate 
• 141377-54-0 2-nitro-1-phenylethan-1-ol 

Downstream Products

• 69308-37-8 (R)-baclofen 
• 63701-55-3 (R)-(-)-baclofen hydrochloride 
• 1201795-62-1 (3S,4R)-ethyl 4-(4-chlorophenyl)-2-oxopyrrolidine-3-carboxylate 
• 1242516-41-1 (3R,4S)-ethyl 4-(phenyl)-2-oxopyrrolidine-3-carboxylate 
• 1207432-20-9 ethyl 3-ethoxy-5-benzyl-1H-pyrazole-4-carboxylate 
• 1198-97-6 4-phenylpyrrolidin-2-one 
• 1078-21-3 4-amino-3-phenylbutanoic acid 
• 1593958-02-1 diethyl 2-(3-phenyl-2H-benzo[1,4]thiazin-2-yl)malonate 
• 71897-07-9 AG₁₂₉₅ 
• 5021-43-2 2-phenylquinoxaline 
• 1593957-91-5 ethyl (2-methyl-5-phenyl-1H-imidazol-4-yl)acetate 
• 94011-49-1 diethyl phenacylmalonate 

Relevant articles and documents

Synthesis and Biological Analysis of Anti-addiction Effect and Hepatotoxicity of Tow Baclofen Analogues Complexed with β-Cyclodextrin

Aim and Objective: The excessive consumption of alcohol and the installation of dependence is, in most cases, facilitated by favorable psychological factors that trigger and maintain the behavior of consumers. Examples more frequently encountered in individuals having difficulty with alcohol are, in particular: one or more anxiety disorders, deficits in the capacities to manage stress and anxiety. The main objective of this work was to study in vivo the anti-addiction effect and hepatotoxicity of tow baclofen analogues complexed with β-Cyclodextrin (βCD) on an alcohol-dependent rat model. Materials and Methods: The synthesis of two analogues, ABF1 and ABF2, close to baclofen was reported. The structural determination of the two compounds was confirmed by NMR and IR analysis. The complexation of analogues with β-Cyclodextrin (βCD) was performed in water at room temperature (25 °C). The interactions of ABF with β-Cyclodextrin, and the stability constant (Ka) of the inclusion complex formed between them were investigated by using UV-visible spectroscopy. The biological effects of baclofen and the two analogues on alcohol dependence were studied in wistar rats. The anti-addiction effect of the analogues was tested by measuring the alcohol intake and the variation of the animal behaviour. The toxicity of the compounds was also analysed on liver injury markers. Results: The amino-3-phenylbutanoic acid (ABF1) and 3,4,5-trihydroxy-N-(methyl-2-acetate) benzamide (ABF2) were synthesized. The complexation of both analogues of baclofen (BF) with β-cyclodextrin (βCD) (ABF-βCD) was realized and confirmed by the stability constant of the inclusion complex (Ka) and Job’s method. The evaluation of anti-addiction activity in vivo showed that ABF1-βCD inhibits the consumption of alcohol at doses equivalent to those of baclofen. Both baclofen analogues have shown an anxiolytic effect. Regarding the toxicity of the two compounds, our results showed that ABF1-βCD has less toxic effect than baclofen; it reduces the activity of ALT and AST enzymes. Histologically, ABF1-βCD has no effect on the liver structure and has a protective effect against lesions alcohol-induced liver disease. Conclusion: Therefore, it can be suggested that ABF1 analogue combined with β-Cyclodextrin can be used as a treatment for alcohol dependence. Further clinical works are needed to confirm its effectiveness.

Metal-Free Deoxygenation of Chiral Nitroalkanes: An Easy Entry to α-Substituted Enantiomerically Enriched Nitriles

A metal-free, mild and chemodivergent transformation involving nitroalkanes has been developed. Under optimized reaction conditions, in the presence of trichlorosilane and a tertiary amine, aliphatic nitroalkanes were selectively converted into amines or nitriles. Furthermore, when chiral β-substituted nitro compounds were reacted, the stereochemical integrity of the stereocenter was maintained and α-functionalized nitriles were obtained with no loss of enantiomeric excess. The methodology was successfully applied to the synthesis of chiral β-cyano esters, α-aryl alkylnitriles, and TBS-protected cyanohydrins, including direct precursors of four active pharmaceutical ingredients (ibuprofen, tembamide, aegeline and denopamine).

Tandem Ring Opening/Cyclization of trans-2-Aryl-3-nitrocyclopropane-1,1-dicarboxylates with 2-Aminopyridines: Access to Pyrido[1,2-a]pyrimidin-4-one Derivatives

A tandem ring-opening/cyclization reaction of trans-2-aryl-3-nitrocyclopropane-1,1-dicarboxylates with 2-aminopyridines was discovered. The reaction did not require the assistance of any catalyst and proceeded more efficiently in water than in organic solvents. This strategy afforded pyrido[1,2-a]pyrimidin-4-one derivatives having a carboxylate group at C3 in 62–90 % yields.